araag2/HINT huggingface dataset:
Clinical trial NCT00419094 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: keppra xr, keppra xr
SMILES: CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects 12 to 75 years of age.

          -  Subjects must have inadequately controlled partial onset epilepsy.

          -  Subjects must be experiencing 2 to 40 seizures per 4-week period while being
             maintained on one or two standard AED(s)

        Exclusion Criteria:

          -  A history of status epilepticus in the 6 months preceding randomization.

          -  Significant medical, psychiatric or neurological illness.

          -  Intake of benzodiazepines on more than an occasional basis

          -  History of previous treatment with levetiracetam or sensitivity to levetiracetam.
Clinical trial NCT00216502 (phase 3, status: completed)
Conditions: alzheimer disease, dementia, mental disorders, brain diseases
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8, G46.8, G94
Drugs: galantamine hydrobromide
SMILES: [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer's disease according to accepted medical standards

          -  Patients with mild to moderate impairment of thinking, reasoning, and judgment as
             defined by a score from 11-24 on the Mini Mental Status Exam (MMSE, a standard
             assessment tool for Alzheimer's disease) Female patients must be post-menopausal

          -  Patients and their caregivers must have signed informed consent forms Exclusion
             Criteria:

          -  Patients with a diagnosis of Parkinson's Disease, Pick's Disease, Huntington's Chorea,
             Creutzfeld-Jacob disease, Down's syndrome, brain cancer, mental retardation, epilepsy,
             psychiatric disease, liver, kidney or heart failure, significant heart, lung,
             digestive, hormone or mental disease or Vitamin B deficiency

          -  Patients with previous severe head injury or blood clot in the brain

          -  Patients who are hospitalized, living in nursing homes or residential care facilities

          -  Patients with brain infections such as abscess, meningitis, encephalitis

          -  Patients with a history of drug or alcohol abuse
Clinical trial NCT01370525 (phase 3, status: completed)
Conditions: heartburn
ICD codes: R12
Drugs: esomeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and non-pregnant ,non-lactating females 18 years or older

          -  Experience heartburn at least 2 days a week

          -  Having heartburn that has responded to heartburn medication

          -  Must discontinue any current heartburn medications

        Exclusion Criteria:

          -  Having a history of erosive esophagitis verified by endoscopy

          -  Having a history of GERD which was diagnosed by a physician

          -  Inability to take study medication or complete the study and all study procedures

          -  Subjects that have required more than one 14-day course of PPI treatment within the
             past 4 months
Clinical trial NCT00159744 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: asenapine, olanzapine, placebo
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a DSMIV diagnosis of bipolar I disorder, current episode manic or mixed.

        Exclusion Criteria:

          -  Patients with unstable medical conditions or clinically significant laboratory
             abnormalities or patients who are rapid cyclers (ie. have had 4 or more (including
             current) mood episodes in the past 12 months); have any other psychiatric disorder
             other than bipolar I disorder as a primary diagnosis.
Clinical trial NCT00209742 (phase 3, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: uft, usel/leucovorin, krestin
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O, [H]C(=O)N1C(CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)NC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with primary colonic carcinoma or rectal carcinoma of histological stage III,
             who have undergone histological curability A or B surgeries

          2. Patients evaluated histologically as lymph node metastasis positive

          3. Patients aged between 20 and 80 years, inclusive, at the time of acquisition of
             informed consent

          4. Patients with performance status 0 to 2

          5. Patients who have not received preoperative cancer therapy (radiotherapy, chemotherapy
             or immunotherapy)

          6. Gastrointestinal function: Patients with no diarrhea (watery stool)

          7. Patients without severe impairment of renal, hepatic and bone marrow functions

          8. Patients with no serious concurrent complications (such as infection)

          9. Patients who have given written informed consent to participate in this study

        Exclusion Criteria:

          1. Patients graded as curability C

          2. Patients with stenosis not capable of oral intake

          3. Among disease stage IIIa cases, those that are si/n(-) and ai/n(-)

          4. Patients with fresh hemorrhage from the gastrointestinal tract

          5. Patients with retention of body fluid necessitating treatment

          6. Patients with infection, intestinal palsy or intestinal occlusion

          7. Patients with the lower end of the tumor involving the peritoneal reflection

          8. Patients with lower rectal cancer (Rb), involving the anal canal (P) or perianal skin
             (E)

          9. Patients with active multiple cancers; or even if the multiple cancers are
             metachronous, have a disease-free period of less than 5 years (but excluding cancer in
             situ and skin cancer)

         10. Patients who are pregnant or hope to become pregnant during the study period

         11. Patients with poorly controlled diabetes or are treated by continuous use of insulin

         12. Patients with a history of ischemic heart disease

         13. Patients with concurrent psychiatric disease or psychotic symptoms, and judged to have
             difficulties participating in the study

         14. Patients receiving continuous administration of steroids

         15. Patients who have experienced serious drug allergy in the past

         16. Others, patients judged by the investigator or subinvestigator to be inappropriate as
             subject
Clinical trial NCT01042769 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: aleglitazar, placebo
SMILES: CO[C@@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C2=CC=CC=C2)C2=C1SC=C2)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults >18 years of age

          -  Type 2 diabetes mellitus

          -  Hospitalization for ACS event and randomization between hospital discharge and 8 weeks
             after the ACS index event (day of hospitalization)

        Exclusion Criteria:

          -  Estimated glomerular filtration rate <45 mL/min/1.73m2

          -  Concomitant treatment with a thiazolidinedione and/or fibrate

          -  Triglycerides >400 mg/dL

          -  Anaemia

          -  Symptomatic congestive heart failure classified as New York Heart Association (NYHA)
             class II-IV (France and Germany: Symptomatic congestive heart failure classified as
             NYHA class I-IV)
Clinical trial NCT00324155 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab, placebo, dacarbazine
SMILES: COC1=CC=CC=C1OCC(O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N1C=CN=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  Measurable Disease

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  Lab / imaging requirements

          -  Neg for Human Immunodeficiency Virus (HIV), Hepatitis B (HepB), C

          -  Men and Women > 18 years (16 were allowable)

          -  Prior therapy restriction (adjuvant only)

        Exclusion:

          -  Pregnant / nursing

          -  Inadequate contraception

          -  Brain metastasis

          -  Primary ocular or mucosal melanoma
Clinical trial NCT01392573 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide, insulin degludec
SMILES: CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  HbA1c (glycosylated haemoglobin) 7.5-10.0% (both inclusive)

          -  Subjects on stable daily doses for at least 90 days prior to trial start of: Basal
             insulin (total daily basal insulin dose within the range of 20-40U in combination
             with: metformin (1500 mg or more or max. tolerated dose) or metformin (1500 mg or more
             or max. tolerated dose) and SU (sulfonylurea) (equal to or more than half of the max.
             approved dose according to local label) or metformin and glinides (equal to or more
             than half of the max. approved dose according to local label)

          -  BMI (Body Mass Index) more than or equal to 27 kg/m^2

        Exclusion Criteria:

          -  Treatment with glucagon like peptide-1 (GLP-1) receptor agonists (e.g. exenatide,
             liraglutide), dipeptidyl peptidase 4 (DPP-4) inhibitors and/or thiazolidinediones
             within 90 days prior to trial start

          -  Impaired liver function

          -  Impaired renal function

          -  Screening calcitonin equal to or above 50 ng/l

          -  Subjects with personal or family history of medullary thyroid carcinoma (MTC) or
             multiple endocrine neoplasia type 2 (MEN 2)

          -  Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis
             of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the
             last 52 weeks prior to trial start and/or planned coronary, carotid or peripheral
             artery revascularisation procedures

          -  Severe uncontrolled treated or untreated hypertension (systolic blood pressure equal
             to or above 180 mm Hg or diastolic blood pressure equal to or above 100 mm Hg)

          -  Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
             according to physician's opinion

          -  History of chronic pancreatitis or idiopathic acute pancreatitis
Clinical trial NCT00658684 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: fesoterodine fumarate
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day
             and urinary urgency episodes >=1 per day.

        Exclusion Criteria:

          -  Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or
             to peanut or soya or any of the excipients.

          -  Patient has a known neurological disease influencing bladder function.

          -  Patient has a complication of lower urinary tract pathology potentially responsible
             for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic
             organ prolapse.
Clinical trial NCT00683800 (phase 3, status: completed)
Conditions: vasomotor symptoms
ICD codes: J30.0
Drugs: desvenlafaxine succinate (dvs) sr, placebo
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy, postmenopausal women who seek treatment for hot flushes

          -  Body Mass Index (BMI) less than or equal to 34 kg/m^2

        Exclusion Criteria:

          -  Hypersensitivity to Venlafaxine

          -  Myocardial infarction an/or unstable angina within 6 months of screening

          -  History of seizure disorder
Clinical trial NCT01135914 (phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Stable Type 1 or Type 2 diabetes mellitus

          -  Visual impairment due to focal or diffuse DME in at least one eye

        Exclusion Criteria:

          -  Active conditions in the study eye that could prevent the improvement of visual acuity
             on study treatment

          -  Active eye infection or inflammation

          -  History of stroke, renal failure or uncontrolled hypertension

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01142726 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, methotrexate, abatacept placebo, methotrexate placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Presence of active clinical synovitis in at least 2 joints, 1 of which must have been
             a small joint, for a minimum of 8 weeks prior to screening

          -  Onset of persistent symptoms ≤ 2 years prior to screening

          -  Positive test result for anticyclic citrullinated peptides 2

          -  Methotrexate naive or with minimum exposure to methotrexate, defined as no more than
             10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit

          -  Biologic naive, including no treatment with an investigational biologic prior to
             screening

          -  Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening

          -  Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or
             sulfasalazine (wash-out) for a minimum of 28 days prior to randomization

          -  If receiving oral corticosteroids, on a stable low dose (≤ 10 mg/day prednisone
             equivalent) for at least 4 weeks

          -  Able to undergo magnetic resonance imaging

        Key Exclusion Criteria:

          -  Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)

          -  Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within
             4 weeks prior to randomization

          -  Scheduled for or anticipating joint replacement surgery

          -  Presence of concomitant illness likely to require systemic glucocorticosteroid therapy
             during the study, in the opinion of the investigator

          -  History of malignancy in the last 5 years

          -  Any serious bacterial infection within the last 3 months not treated or resolved with
             antibiotics, or any chronic or recurrent bacterial infection

          -  At risk for tuberculosis

          -  Evidence of active or latent bacterial or viral infection at the time of potential
             enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus
             that resolved less than 2 months prior to enrollment
Clinical trial NCT00499590 (phase 3, status: terminated)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: bevasiranib, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must be age 50 years or older

          2. Patients must have predominantly classic, minimally classic or occult with no classic
             lesions secondary to Age Related Macular Degeneration.

          3. The study eye must have ETDRS best corrected visual acuity of 69 to 24 letters (20/40
             to 20/320 Snellen equivalent).

          4. Patients must be willing and able to return for scheduled monthly follow-up visits for
             two-years.

        Exclusion Criteria:

          1. Prior pharmacologic treatment for AMD in the study (patients can not have previously
             received Avastin®/Lucentis®, Macugen®, or any other anti-VEGF agents, steroid
             treatments, PDT, radiation treatment, or any experimental therapies for AMD in the
             study eye)

          2. Any intraocular surgery of the study eye within 12 weeks of screening

          3. Previous posterior vitrectomy of the study eye

          4. Advanced glaucoma or intraocular pressure above 22 mm Hg in the study eye despite
             treatment.
Clinical trial NCT01144364 (phase 3, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab [mabthera/rituxan]
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 60-75 years of age;

          -  B-cell follicular NHL;

          -  no previous treatment;

          -  active disease, with rapid progression.

        Exclusion Criteria:

          -  other cancer within 3 years of study, except carcinoma in situ of the cervix, basal or
             squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of
             the breast treated with lumpectomy;

          -  long-term use (>1 month) of systemic corticosteroids;

          -  central nervous system involvement;

          -  history of significant cardiovascular disease;

          -  positive test result for HIV, or hepatitis B or C.
Clinical trial NCT00610675 (phase 3, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: org 50081
SMILES: [H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  sign written informed consent after the scope and nature of the investigation have
             been explained to them, before any trial-related evaluations;

          -  completed Protocol P05706 or P05707;

          -  Have safety and efficacy assessments conducted per protocol P05706 or P05707.

        Exclusion Criteria:

          -  clinically relevant electrocardiogram (ECG) abnormalities as judged by the
             investigator;

          -  clinically relevant abnormal laboratory values as judged by the investigator;

          -  any adverse event deemed relevant for exclusion in Protocol P05708 as judged by the
             investigator or,

          -  were significantly non compliant with protocol criteria and procedures of Protocol
             P05706 or P05707, as judged by the investigator.
Clinical trial NCT00369343 (phase 3, status: completed)
Conditions: depression, depressive disorder, depressive disorder, major
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: desvenlafaxine administered as a succinate salt in a sustained-release form (dvs sr), placebo
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Peri- and postmenopausal women between the ages of 40 and 70 years, inclusive.

          -  A primary diagnosis of MDD, single or recurrent episode, without psychotic features
             using the modified International Neuropsychiatric Interview (MINI).

          -  Montgomery-Asberg Depression Rating Scale (MADRS) total score > or = 22 at the
             screening and baseline visit.

        Exclusion Criteria:

          -  Use of oral estrogen-, progestin-, androgen-, or Selective Estrogen Receptor Modulator
             (SERM)-containing drug products 8 weeks before baseline.

          -  Current (within 12 months) psychoactive substance abuse or dependence (including
             alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive
             disorder, or a lifetime diagnosis of bipolar or psychotic disorder.

          -  A history or active presence of clinically important medical disease.

        Additional criteria apply.